Evidence map›Paper›PMID 39047913›Full record

ArticleInternational journal of antimicrobial agents2024

Zanamivir and baloxavir combination to cure persistent influenza and coronavirus infections after hematopoietic stem cell transplant.

Victor Euzen, Aliénor Xhaard, Samar Berreira-Ibraim, Laure Deville, Aude Quentin, Pedro Hendrique De Lima Prata, Viviane Gournay, Matthieu Prot, Yannis Rahou, Marion Barbet and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of antimicrobial agents, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. PA and PA-X: two key proteins from segment 3 of the influenza viruses.Frontiers in cellular and infection microbiology · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Victor EuzenVirology Department, AP-HP, Hôpital Saint Louis, Paris, France.
Aliénor XhaardHematology Transplantation, AP-HP, Hôpital Saint Louis, Paris, France.
Samar Berreira-IbraimInstitut Pasteur, National Reference Center for Respiratory Viruses, Paris, France.
Laure DevillePharmacy, AP-HP, Hôpital Saint-Louis, Paris, France.
Aude QuentinHematology, Hôpital Jean Jaures, Paris, France.
Pedro Hendrique De Lima PrataHematology Transplantation, AP-HP, Hôpital Saint Louis, Paris, France.
Viviane GournayHematology Transplantation, AP-HP, Hôpital Saint Louis, Paris, France.
Matthieu ProtInstitut Pasteur, Université Paris Cité, G5 Evolutionary Genomics of RNA Viruses, Paris, France.
Yannis RahouInstitut Pasteur, National Reference Center for Respiratory Viruses, Paris, France.
Marion BarbetInstitut Pasteur, National Reference Center for Respiratory Viruses, Paris, France.
Séverine Mercier-DelarueVirology Department, AP-HP, Hôpital Saint Louis, Paris, France.
Régis Peffault De La TourHematology Transplantation, AP-HP, Hôpital Saint Louis, Paris, France.
Etienne Simon-LoriereInstitut Pasteur, National Reference Center for Respiratory Viruses, Paris, France; Institut Pasteur, Université Paris Cité, G5 Evolutionary Genomics of RNA Viruses, Paris, France.
Jérôme LegoffVirology Department, AP-HP, Hôpital Saint Louis, Paris, France; Université Paris Cité, Inserm U976, Insight team, Paris, France. Electronic address: jerome.le-goff@aphp.fr.

Funding

Inter-regional study of transmission, adaptation and pathogenesis of viruses with pandemic potential in Southeast Asia and West/Central AfricaU01AI151758 · NIAID · INSTITUT PASTEUR · PI SAKUNTABHAI, ANAVAJ, SIMON-LORIERE, ETIENNE · 2020 to 2024
$6.7M
NIAID NIH HHS U01 AI151758
6 · The paper itself

Abstract

objectivesImmunocompromised patients may experience prolonged shedding of influenza virus potentially leading to severe infections. Alternatives to monotherapy with neuraminidase inhibitors should be evaluated to entirely suppress viral replication and prevent drug-resistant mutations.

methodsWe investigated the clinical and virological evolution in a case of persistent influenza A and human coronavirus OC43 (HCoV-OC43) coinfection in a hematopoietic stem cell transplant recipient after different therapeutic strategies.

resultsSuccessive oseltamivir and zanamivir monotherapies failed to control both infections, with positive results persisting for over 110 days each. This led to the emergence of highly resistant oseltamivir strains due to neuraminidase mutations (E119V and R292K) followed by a deletion (del245-248), while maintaining sensitivity to zanamivir. The intra-host viral diversity data showed that the treatments impacted viral diversity of influenza virus, but not of HCoV-OC43. Considering the patient's underlying condition and the impact of prolonged viral shedding on pulmonary function, eradicating the influenza virus was necessary. A 10-day regimen combining zanamivir and baloxavir-marboxil effectively controlled influenza virus replication and was associated with the clearance of HCoV-OC43, finally resulting in comprehensive respiratory recovery.

conclusionThese observations underscore the importance of further investigating combination treatments as the primary approach to achieve influenza eradication in immunocompromised patients.

Indexed as

Antiviral AgentsDibenzothiepinsHematopoietic Stem Cell TransplantationInfluenza, HumanMorpholinesPyridonesTriazinesZanamivirCoronavirus InfectionsCoronavirus OC43, HumanDrug Resistance, ViralDrug Therapy, CombinationFemaleHumansImmunocompromised HostInfluenza A virusAntiviral AgentsbaloxavirDibenzothiepinsMorpholinesPyridonesTriazinesZanamivirBaloxavir-marboxilDrug-resistantInfluenzaNeuraminidase inhibitorTransplantation

Identifiers

PMID39047913
PMCPMC12415407

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.